Concepedia
Multiple Sclerosis and Related Disorders · 2012 · 28 citations · 7 references
Life SciencesNeurologyNeurodegenerationNeuroimmunologyMultiple SclerosisMultiple Sclerosis PharmacotherapyMultiple Sclerosis ImmunopathogenesisMultiple Sclerosis TherapyOral TreatmentRelapsing-remitting Multiple Sclerosis Treatment
7
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos, Ernst‐Wilhelm Radue, Paul O’Connor et al. · New England Journal of Medicine · 2010 · 2.6K citations · Full text
Life Sciences, Neurology, Pharmacotherapy +14
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker, De-Hyung Lee, Sarah Ryan et al. · Brain · 2011 · 1.2K citations · Full text
Life Sciences, Neuroscience, Pharmacology +17
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Paul O’Connor, Andrew Goodman, Ludwig Kappos et al. · Neurology · 2011 · 297 citations
Life Sciences, Neurology, Pharmacotherapy +15
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
Werner Wenning, Aiden Haghikia, Jörg Laubenberger et al. · New England Journal of Medicine · 2009 · 178 citations
Life Sciences, Neurology, Pharmacotherapy +17
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Augusto Miravalle, Rikke Beck Jensen, R. Philip Kinkel · Archives of Neurology · 2010 · 174 citations
Life Sciences, Immunology, Neurology +16